Compare American Financial Group Inc (AFG) vs ARK Genomic Revolution ETF (ARKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Financial Group Inc vs ARK Genomic Revolution ETF — how do they compare? American Financial Group Inc trades at $144.91 (market cap $11.97B), while ARK Genomic Revolution ETF trades at $44.6. The key difference: American Financial Group Inc pays a 2.44% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, American Financial Group Inc nearer its low. Which is the better fit depends on your goals.
| AFG | ARKG | |
|---|---|---|
Market Cap | $11.97B | — |
Sector | Financials | Sector/Thematic |
52-Week High | $148.71 | $44.55 |
52-Week Low | $124.18 | $24.02 |
Enterprise Value | $12.35B | — |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Financial Group (AFG) trades at $144.82, up 0.66% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong Q2 2026 earnings of $2.82 per share, beating estimates, driven by property and casualty underwriting and investment income. Revenue for 2025 was $8.12 billion with a net income margin of 10.37%, while 2026 is projected at $8.2 billion with an 11.66% margin. Analysts have a consensus price target of $160.67, with 41% recommending buy.
AFG presents a positive outlook with solid earnings beats and a shareholder-friendly dividend policy, but faces risks from competitive pressures and potential market volatility. The stock's current valuation at a P/E of 12.62 offers room for growth relative to historical averages, supported by institutional interest and consistent cash flow generation.
ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.
Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Financial Group Inc
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →
